Osteoporosis in men with hypogonadism because of ApoA-I Leu75Pro amyloidosis under long-term testosterone therapy.
amyloidosis
apolipoprotein A-I
bone
male hypogonadism
osteoporosis
testosterone
Journal
Andrology
ISSN: 2047-2927
Titre abrégé: Andrology
Pays: England
ID NLM: 101585129
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
revised:
11
12
2022
received:
29
09
2022
accepted:
22
12
2022
medline:
8
8
2023
pubmed:
10
1
2023
entrez:
9
1
2023
Statut:
ppublish
Résumé
Apo A-I Leu75Pro amyloidosis is a rare systemic hereditary disease, whose hallmark and earliest involvement is testicular impairment, characterized by hypogonadism and macrorchidism; renal and hepatic involvement are the other characteristics. To evaluate for the first time the prevalence of osteopenia, osteoporosis and vertebral fractures (VFs) in men with this form of amyloidosis affected by hypogonadism and under long-term testosterone replacement therapy (TRT). Retrospective study on 50 men >50 years (median age 64.5) with dual-energy X-ray absorptiometry (DXA), hormonal, and biochemical data available at least 3 years after the start of TRT. Serum gonadal hormones and bone markers, lumbar and femoral DXA-scan with morphometric assay for evaluation of VFs were assessed. At 7.5 years from start of TRT, lumbar and/or femoral osteopenia and osteoporosis were found in 54% and 10% of patients, respectively. Of the men who had the morphometric assay performed, five of 34 (14.7%) had VFs. Compared to patients with normal bone mineral density, men with osteopenia and osteoporosis were older, had lower body mass index, higher sex hormone binding globulin and showed more frequently renal involvement. Multiorgan involvement, without different TRT dosage, was associated with lower testosterone levels. Men with hypogonadism because of Apo A-I Leu75Pro amyloidosis under long-term TRT had a high burden of low bone mass (64%) and VFs (almost 15%). Osteopenia-osteoporosis was more frequently observed in older patients with multi-organ disease, which might contribute to impair bone health beyond hypogonadism.
Sections du résumé
BACKGROUND
Apo A-I Leu75Pro amyloidosis is a rare systemic hereditary disease, whose hallmark and earliest involvement is testicular impairment, characterized by hypogonadism and macrorchidism; renal and hepatic involvement are the other characteristics.
OBJECTIVE
To evaluate for the first time the prevalence of osteopenia, osteoporosis and vertebral fractures (VFs) in men with this form of amyloidosis affected by hypogonadism and under long-term testosterone replacement therapy (TRT).
MATERIALS AND METHODS
Retrospective study on 50 men >50 years (median age 64.5) with dual-energy X-ray absorptiometry (DXA), hormonal, and biochemical data available at least 3 years after the start of TRT. Serum gonadal hormones and bone markers, lumbar and femoral DXA-scan with morphometric assay for evaluation of VFs were assessed.
RESULTS
At 7.5 years from start of TRT, lumbar and/or femoral osteopenia and osteoporosis were found in 54% and 10% of patients, respectively. Of the men who had the morphometric assay performed, five of 34 (14.7%) had VFs. Compared to patients with normal bone mineral density, men with osteopenia and osteoporosis were older, had lower body mass index, higher sex hormone binding globulin and showed more frequently renal involvement. Multiorgan involvement, without different TRT dosage, was associated with lower testosterone levels.
DISCUSSION AND CONCLUSION
Men with hypogonadism because of Apo A-I Leu75Pro amyloidosis under long-term TRT had a high burden of low bone mass (64%) and VFs (almost 15%). Osteopenia-osteoporosis was more frequently observed in older patients with multi-organ disease, which might contribute to impair bone health beyond hypogonadism.
Substances chimiques
Apolipoprotein A-I
0
Testosterone
3XMK78S47O
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1077-1085Informations de copyright
© 2023 American Society of Andrology and European Academy of Andrology.
Références
Benson MD. The hereditary amyloidoses. Best Pract Res Clin Rheumatol. 2003;17(6):909-927. https://doi.org/10.1016/j.berh.2003.09.001
Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349(6):583-596. https://doi.org/10.1056/NEJMra023144
Obici L, Perfetti V, Palladini G, Moratti R, Merlini G. Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta. 2005;1753(1):11-22. https://doi.org/10.1016/j.bbapap.2005.08.014
Obici L, Franceschini G, Calabresi L, et al. Structure, function and amyloidogenic propensity of apolipoprotein A-I. Amyloid. 2006;13(4):191-205. https://doi.org/10.1080/13506120600960288
Sipe JD, Benson MD, Buxbaum JN, et al. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid. 2016;23(4):209-213. https://doi.org/10.1080/13506129.2016.1257986
Murphy CL, Wang S, Weaver K, Gertz MA, Weiss DT, Solomon A. Renal apolipoprotein A-I amyloidosis associated with a novel mutant Leu64Pro. Am J Kidney Dis. 2004;44(6):1103-1109. https://doi.org/10.1053/j.ajkd.2004.08.033
Eriksson M, Schönland S, Yumlu S, et al. Hereditary apolipoprotein AI-associated amyloidosis in surgical pathology specimens: identification of three novel mutations in the APOA1 gene. J Mol Diagn. 2009;11(3):257-262. https://doi.org/10.2353/jmoldx.2009.080161
Moutafi M, Ziogas DC, Michopoulos S, et al. A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options. BMC Med Genet. 2019;20(1):23. https://doi.org/10.1186/s12881-019-0755-5
Yoshinaga T, Katoh N, Yazaki M, et al. Giant hepatomegaly with spleno-testicular enlargement in a patient with apolipoprotein A-I amyloidosis: an uncommon type of amyloidosis in Japan. Intern Med. 2021;60(4):575-581. https://doi.org/10.2169/internalmedicine.5126-20
Del Giudice R, Arciello A, Itri F, et al. Protein conformational perturbations in hereditary amyloidosis: differential impact of single point mutations in ApoAI amyloidogenic variants. Biochim Biophys Acta. 2016;1860(2):434-444. https://doi.org/10.1016/j.bbagen.2015.10.019
Gregorini G, Izzi C, Obici L, et al. Renal apolipoprotein A-I amyloidosis: a rare and usually ignored cause of hereditary tubulointerstitial nephritis. J Am Soc Nephrol. 2005;16(12):3680-3686. https://doi.org/10.1681/ASN.2005040382
Scalvini T, Martini PR, Gambera A, et al. Spermatogenic and steroidogenic impairment of the testicle characterizes the hereditary leucine-75-proline apolipoprotein a-I amyloidosis. J Clin Endocrinol Metab. 2008;93(5):1850-1853. https://doi.org/10.1210/jc.2007-1656
Coriu D, Dispenzieri A, Stevens FJ, et al. Hepatic amyloidosis resulting from deposition of the apolipoprotein A-I variant Leu75Pro. Amyloid. 2003;10(4):215-223. https://doi.org/10.3109/13506120309041738
Delbarba A, Facondo P, Fisogni S, et al. Testicular involvement is a hallmark of Apo A-I Leu75Pro mutation amyloidosis. J Clin Endocrinol Metab. 2020;105(12):dgaa587. https://doi.org/10.1210/clinem/dgaa587
Gregorini G, Izzi C, Ravani P, et al. Tubulointerstitial nephritis is a dominant feature of hereditary apolipoprotein A-I amyloidosis. Kidney Int. 2015;87(6):1223-1229. https://doi.org/10.1038/ki.2014.389
Obici L, Palladini G, Giorgetti S, et al. Liver biopsy discloses a new apolipoprotein A-I hereditary amyloidosis in several unrelated Italian families. Gastroenterology. 2004;126(5):1416-1422. https://doi.org/10.1053/j.gastro.2004.03.003
Rochira V, Antonio L, Vanderschueren D. EAA clinical guideline on management of bone health in the andrological outpatient clinic. Andrology. 2018;6(2):272-285. https://doi.org/10.1111/andr.12470
Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. https://doi.org/10.1210/jc.2018-00229
Corona G, Goulis DG, Huhtaniemi I, et al. European Academy of Andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males: endorsing organization: European Society of Endocrinology. Andrology. 2020;8(5):970-987. https://doi.org/10.1111/andr.12770
Isidori AM, Aversa A, Calogero A, et al. Adult- and late-onset male hypogonadism: the clinical practice guidelines of the Italian Society of Andrology and Sexual Medicine (SIAMS) and the Italian Society of Endocrinology (SIE). J Endocrinol Invest. 2022;45(12):2385-2403. https://doi.org/10.1007/s40618-022-01859-7
Lotti F, Maggi M. Ultrasound of the male genital tract in relation to male reproductive health. Hum Reprod Update. 2015;21(1):56-83. https://doi.org/10.1093/humupd/dmu042
Pedrazzoni M, Girasole G, Bertoldo F, et al. Definition of a population-specific DXA reference standard in Italian women: the Densitometric Italian Normative Study (DINS). Osteoporos Int. 2003;14(12):978-982. https://doi.org/10.1007/s00198-003-1521-1
Camacho PM, Petak SM, Binkley N, et al. American association of clinical endocrinologists/american college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pract. 2020;26(1):1-46. https://doi.org/10.4158/GL-2020-0524SUPPL
Genant HK, Jergas M. Assessment of prevalent and incident vertebral fractures in osteoporosis research. Osteoporos Int. 2003;14(3):S43-S55. https://doi.org/10.1007/s00198-002-1348-1
Conceição IM, Miranda LC, Simões E, Gouveia RG, Evangelista TD, de Carvalho MA. Bone mineral density in familial amyloid polyneuropathy and in other neuromuscular disorders. Eur J Neurol. 2005;12(6):480-482. https://doi.org/10.1111/j.1468-1331.2005.01059.x
Tomás MT, Santa-Clara MH, Monteiro E, et al. Body composition, muscle strength, functional capacity, and physical disability risk in liver transplanted familial amyloidotic polyneuropathy patients. Clin Transplant. 2011;25(4):E406-414. https://doi.org/10.1111/j.1399-0012.2011.01436.x
Porcelli T, Maffezzoni F, Pezzaioli LC, Delbarba A, Cappelli C, Ferlin A. Management of endocrine disease: male osteoporosis: diagnosis and management - should the treatment and the target be the same as for female osteoporosis? Eur J Endocrinol. 2020;183(3):R75-R93. https://doi.org/10.1530/EJE-20-0034
Corona G, Vena W, Pizzocaro A, et al. Testosterone supplementation and bone parameters: a systematic review and meta-analysis study. J Endocrinol Invest. 2022;45(5):911-926. https://doi.org/10.1007/s40618-021-01702-5
Rochira V. Late-onset hypogonadism: bone health. Andrology. 2020;8(6):1539-1550. https://doi.org/10.1111/andr.12827
Hsu CY, Chen LR, Chen KH. Osteoporosis in patients with chronic kidney diseases: a systemic review. Int J Mol Sci. 2020;21(18). https://doi.org/10.3390/ijms21186846
Golds G, Houdek D, Arnason T. Male hypogonadism and osteoporosis: the effects, clinical consequences, and treatment of testosterone deficiency in bone health. Int J Endocrinol. 2017;2017:4602129. https://doi.org/10.1155/2017/4602129
Miller PD. Bone disease in CKD: a focus on osteoporosis diagnosis and management. Am J Kidney Dis. 2014;64(2):290-304. https://doi.org/10.1053/j.ajkd.2013.12.018
Cannata-Andía JB, Martín-Carro B, Martín-Vírgala J, et al. Chronic kidney disease-mineral and bone disorders: pathogenesis and management. Calcif Tissue Int. 2021;108(4):410-422. https://doi.org/10.1007/s00223-020-00777-1
Sobh MM, Abdalbary M, Elnagar S, et al. Secondary osteoporosis and metabolic bone diseases. J Clin Med. 2022;11(9):2382. https://doi.org/10.3390/jcm11092382
Maffezzoni F, Porcelli T, Delbarba A, et al. Hypogonadism and bone health in men with HIV. Lancet HIV. 2020;7(11):e782-e790. https://doi.org/10.1016/S2352-3018(20)30236-8
Pezzaioli LC, Porcelli T, Delbarba A, et al. Impact of hypogonadism on bone mineral density and vertebral fractures in HIV-infected men. J Endocrinol Invest. 2021;45(2):433-443. https://doi.org/10.1007/s40618-021-01665-7
Bojesen A, Birkebaek N, Kristensen K, et al. Bone mineral density in Klinefelter syndrome is reduced and primarily determined by muscle strength and resorptive markers, but not directly by testosterone. Osteoporos Int. 2011;22(5):1441-1450. https://doi.org/10.1007/s00198-010-1354-7
Santi D, Crépieux P, Reiter E, et al. Follicle-stimulating hormone (FSH) action on spermatogenesis: a focus on physiological and therapeutic roles. J Clin Med. 2020;9(4):1014. https://doi.org/10.3390/jcm9041014
Santi D, Madeo B, Carli F, et al. Serum total estradiol, but not testosterone is associated with reduced bone mineral density (BMD) in HIV-infected men: a cross-sectional, observational study. Osteoporos Int. 2016;27(3):1103-1114. https://doi.org/10.1007/s00198-015-3383-8